These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19815307)

  • 1. Personalized medicine: factors influencing reimbursement.
    Meckley LM; Neumann PJ
    Health Policy; 2010 Feb; 94(2):91-100. PubMed ID: 19815307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.
    Merlin T; Farah C; Schubert C; Mitchell A; Hiller JE; Ryan P
    Med Decis Making; 2013 Apr; 33(3):333-42. PubMed ID: 22895559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic tests: the need for a level playing field.
    Pirmohamed M; Hughes DA
    Nat Rev Drug Discov; 2013 Jan; 12(1):3-4. PubMed ID: 23274456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
    Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
    Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Framework for Prioritizing Research Investments in Precision Medicine.
    Basu A; Carlson JJ; Veenstra DL
    Med Decis Making; 2016 Jul; 36(5):567-80. PubMed ID: 26502985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.
    Koleva-Kolarova R; Buchanan J; Vellekoop H; Huygens S; Versteegh M; Mölken MR; Szilberhorn L; Zelei T; Nagy B; Wordsworth S; Tsiachristas A;
    Appl Health Econ Health Policy; 2022 Jul; 20(4):501-524. PubMed ID: 35368231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).
    Hutton J; McGrath C; Frybourg JM; Tremblay M; Bramley-Harker E; Henshall C
    Int J Technol Assess Health Care; 2006; 22(1):10-8. PubMed ID: 16673675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of precision medicine: a scoping review.
    Kasztura M; Richard A; Bempong NE; Loncar D; Flahault A
    Int J Public Health; 2019 Dec; 64(9):1261-1271. PubMed ID: 31650223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of genetic tests in the era of personalized medicine].
    Molnár JM; Magyarósi S; Németh G
    Magy Onkol; 2013 Mar; 57(1):16-20. PubMed ID: 23573517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges.
    Knowles L; Luth W; Bubela T
    J Law Biosci; 2017 Dec; 4(3):453-506. PubMed ID: 29868182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ask not what personalized medicine can do for you--ask what you can do for personalized medicine.
    Budin-Ljøsne I; Harris JR
    Public Health Genomics; 2015; 18(3):131-8. PubMed ID: 25766382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests.
    Ramsey SD; Veenstra DL; Garrison LP; Carlson R; Billings P; Carlson J; Sullivan SD
    Am J Manag Care; 2006 Apr; 12(4):197-202. PubMed ID: 16610921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.